International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 34-42 www.ijprajournal.com ISSN: 2456-4494

The Recent Advances in the Approach of Artificial Intelligencetowards Medicine Discovery

Puja L.Choundhe, Payal A.Dhoke, Rutuja B. Deshpande, Praktan S.Dahekar , Tushar C. Dangare.

BACHLOR OF PHARMACY
Dr. Babasaheb Ambedkar Technological University
CHH.SAMBHAJINAGAR, MAHARASHTRA.

Date of Submission: 01-05-2025 Date of Acceptance: 10-05-2025

ABSTRACT:
Artificial intelligence (AI) has recently emerged as a transformative force in the field of medicine, playing a pivotal role in advancing drug discovery. AI offers groundbreaking opportunities for improving accuracy, efficiency, and innovation in this domain. With its integration into drug development processes, AI has the potential to revolutionize how new treatments are discovered and designed. Over recent years, the use of AI techniques in drug discovery has significantly expanded. Tools like combinatorial QSAR and QSPR models, virtual screening, and de novo drug design are gaining traction for their ability to analyze and predict complex molecular interactions. These advancements not only streamline research processes but also enhance precision in identifying promising drug candidates.This review aims to provide a comprehensive overview of AI-driven drug discovery and its various applications. It also sheds light on the limitations of traditional drug design methods and identifies key gaps that AI can address. Additionally, we discuss current challenges, such as ethical concerns and limited access to quality data, and propose potential strategies to overcome these obstacles. By exploring the transformative potential of AI in this field, we hope to foster a deeper understanding of its capabilities and inspire further innovation in drug discovery processes briefly outlined in this article.

I. INTRODUCTION

Drug discovery remains one of the most challenging and resource-intensive endeavors in medical science, typically requiring billions of dollars and more than a decade of work to bring a single drug to market. Despite numerous advancements, traditional approaches often fall short due to their reliance on high-throughput screening and laborious trial-and-error methods. These limitations have driven the search for innovative solutions, with artificial intelligence (AI) emerging as a transformative force in the field.

AI's unique ability to process vast amounts of data and identify complex patterns offers unprecedented opportunities to optimize various stages of drug development. From mapping protein structures and virtual screening to de novo drug design and toxicity prediction, AI has introduced new efficiencies and insights that were previously unattainable. However, these technological advancements also come with challenges, such as data accessibility, algorithm transparency, and ethical considerations, which must be addressed to ensure equitable and effective implementation. the role of AI in revolutionizing drug discovery, emphasizing its applications, limitations, and future potential. bridging traditional methodologieswith cutting-edge technology, AI has the capacity to not only expedite the drug development process but also pave the way for more personalized and precise healthcare solutions.



Overview of Artificial Intelligence in Drug Discovery

Recent advancements in artificial intelligence (AI) and machine learning (ML) have transformed the landscape of drug discovery, bringing unparalleled efficiency to the process. By integrating AI with ML, innovative solutions have been introduced to overcome persistent challenges of traditional methodologies and to streamline the identification of viable drug candidates.

AI, a branch of computer science, focuses on creating intelligent systems capable of performing tasks traditionally requiring human intelligence. In drug discovery, machine learning a core subset of AI-plays a pivotal role by analyzing extensive datasets and extracting meaningful insights. This approach accelerates the discovery process, making it more efficient and data-driven than ever before. These advancements in AI and ML signify a new era in pharmaceutical innovation, offering the potential to address longstanding inefficiencies and propel drug development forward..

Machine Learning (ML): Machine learning is a subset of AI where algorithms are trained to learn from data and make predictions or decisions without explicit programming. In drug discovery, ML is used for predicting molecular bioactivity, toxicity, and pharmacokinetics. Supervised learning models, for instance, are trained using labeled datasets of known compounds and their effects on biological systems to predict outcomes for new compounds

Deep Learning (DL): A more advanced branch of ML, deep learning uses artificial neural networks with multiple layers to model complex relationships. It is particularly useful in tasks like protein folding prediction, drug-target interaction modeling, and high-dimensional data analysis such as genomics and proteomics. Deep learning has been instrumental in the development of tools like AlphaFold, which predicts the 3D structure of proteins with unprecedented accuracy.

Natural Language Processing (NLP): NLP enables AI systems to interpret and extract information from textual data such as research papers, clinical trial reports, and electronic health records. This technology accelerates knowledge extraction, enabling the identification of new drug targets, repurposing opportunities, and unearthing hidden insights within the vast amount of scientific literature.

Reinforcement Learning (RL): RL is an optimization technique that uses trial and error to find optimal solutions. In drug discovery, RL is utilized to design novelmolecules by predicting the most effective chemical modifications to enhance the desired properties of a drug candidate, such as binding affinity or stability.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 34-42 www.ijprajournal.com ISSN: 2456-4494



Data-Driven Approaches to Efficacy Prediction:

ML models are trained on large datasets, including information about molecular structure, chemical properties, and biological activities. These datasets may come from diverse sources, such as chemical libraries, biological assays, or even clinical trial results.Algorithms such assupervised learning (e.g., decision trees, support vector machines, and neural networks) are used to classify compounds based on their likelihood of inducing a therapeutic effect in specific diseases.One key advantage of ML in efficacy prediction is its ability to identify patterns in high-dimensional data that are difficult for humans to discern. For instance, deep learning techniques can model complex molecular interactions with greater accuracy than traditional methods.In medicinal chemistry, artificial intelligence (AI) plays a crucial role in predicting the efficacy and toxicity of potential drug candidates. By leveraging AI, especially through deep learning (DL) algorithms, the drug development process has become faster, surpassing the time constraints of traditional methods . For instance, deep learning models, trained on large datasets of known drugs, can accurately predict the activity of new compounds . Additionally, AI has made significant strides in preventing the toxicity of drug candidates by utilizing databases of known toxic and non-toxic compoundsAI is also pivotal in identifying drug–drug interactions, especially in patients with multiple conditions. It can detect adverse reactions that may arise from the combination of different drugs, whether for the same or different diseases .



Over the past decade, drug discovery has evolved from a labor-intensive process reliant on high-throughput screening and trial-and-error methods to one that increasingly integrates advanced technologies like machine learning (ML) and natural language processing (NLP). These innovations promise to significantly enhance the efficiency and accuracy of analyzing large datasets, improving the precision of drug discovery. The recent success of deep learning models in predicting the efficacy of drug compounds highlights the transformative potential of artificial intelligence (AI) in this field. Furthermore, AI has demonstrated the capability to model various factors that could impact drug effectiveness, which opens new possibilities for optimizing the drug development process.Despite the progress, challenges remain, including ethical concerns. Research continues to explore how AI can be leveraged to design novel bioactive compounds. While these advancements are promising, the field still faces obstacles that require attention, particularly in balancing innovation with ethical considerations.AI, in its current form, can be defined as any computer system or machine exhibiting behaviors that mimic human intelligence, often

Drug toxicity prediction

The prediction of drug toxicity is a critical component of the drug development process, aimed at identifying and evaluating potential adverse effects or reactions before a drug progresses further in the development pipeline. Accurate prediction of drug toxicity is essential for ensuring the safety and well-being of patients who will ultimately use the drug. Traditionally, drug toxicity prediction relied heavily on experimental research and animal testing. However, these methods are time-consuming, costly, and may not always replicate human responses accurately. With the advent of machine learning (ML), the prediction of drug toxicity is undergoing a transformative shift.Modern approaches use large datasets, including chemical properties, biological pathways, and known toxicity profiles, to predict potential risks associated with drugs. Machine learning algorithms, such as support vector machines, random forests, and neural networks, are trained on these extensive datasets to identify patterns and relationships that signal potential toxicity.The integration of artificial intelligence (AI) into drug toxicity prediction offers numerous advantages. It enables the analysis of large, complex datasets, providing a deeper understanding of the intricate interactions between drugs and biological systems. Machine learning models can detect hidden patterns and relationships that might not be evident through traditional methods. Furthermore, these models can accelerate the identification of potential toxicities in new drug candidates, which is crucial during the drug development phase.Despite these advancements, challenges remain, including the need for high-quality data, the diversity of training datasets, and the evaluation of complex AI models. Ethical considerations and regulatory standards are also important in integrating AI-based toxicity prediction into the drug development process. Nevertheless, AI-driven drug toxicity prediction holds significant promise in enhancing the safety and success of new pharmaceuticals. Continued research and collaboration among researchers, data scientists, and regulatory bodies are essential to ensure the accuracy of toxicity predictions and the progress of this field. with ethical considerations.AI, in its current form, can be defined as any computer system or machine exhibiting behaviors that mimic human intelligence, often referred to as robotics or automation. While robotic systems are designed to carry out repetitive, complex tasks, AI is focused on endowing machines with cognitive abilities such as problem-solving, learning, organizing information, and even language comprehension. Presently, narrow AI, or "weak AI," is specialized for specific tasks like web searches, facial and voice recognition, and automated diagnostics. Looking ahead, the goal of the AI community is to create machines capable of outperforming humans in a broad range of cognitive functions, ultimately leading to the creation of strong or general AI.

Virtual screening: a lead identification approach

Virtual Screening (VS) is a powerful technique used for lead identification in AI-driven drug discovery. This method involves computationally screening millions of compounds that resemble known drugs or leads against well-characterized proteins. Docking techniques are employed to assess the affinity of ligands for binding to the target protein. The compounds that show promising results in the virtual screening phase are then subjected to in vitro testing.In AI-based drug discovery, virtual screening can be categorized into two main types: ligand-based virtual screening (LBVS) and structure-based virtual screening (SBVS). LBVS focuses on analyzing biological data to distinguish between inactive and active compounds. It utilizes a consensus pharmacophore, similarity measures, or other descriptors to identify highly active scaffolds.Using computer algorithms, a target protein is docked with a large library of commercially available drug-like compounds. The docking process is then scored through a scoring function, and the results are confirmed through experimental validation assays.One of the primary functions of SBVS is the scoring of ligands. Unlike ligand-based approaches, which often rely on existing experimental data, structure-based methods do not require prior knowledge of experimental results, making them particularly useful for discovering new drug candidates.

De-novo drug design with artificial intelligence

The creation of novel molecular entities with specific pharmacological properties, known as de-novo drug design, presents a significant challenge in computer-assisted drug discovery. The vast chemical space, which spans from 10^60 to 10^100 potential drug-like molecules, adds complexity to the task. Traditional drug design methods, whether structure-based or ligand-based, have been crucial in discovering small-molecule drug candidates, but they have limitations. These approaches often depend on templates derived from active sites or pharmacophores, which can restrict the range of possible drug candidates.The introduction of artificial intelligence (AI) has significantly advanced de-novo drug design. AI models, such as ReLeaSE, ChemVAE, Graph INVENT, and MolRNN, use various molecular representations to accelerate the drug discovery process by efficiently exploring chemical space. These methods are typically categorized as either ligand-based or structure-based, employing rule-based or rule-free techniques. Rule-based methods rely on predefined construction rules, while rule-free approaches, often powered by generative deep learning models, sample molecules from learned latent representations of molecular data.Generative models, such as recurrent neural networks and variational autoencoders, have proven effective at exploring chemical space. Evaluation of these models typically considers criteria such as validity, novelty, similarity to known compounds, and scaffold diversity. One promising approach combines both rule-based and rule-free methods to design bioactive and synthesizable molecular entities. While most current research focuses on ligand-based approaches, there is increasing interest in structure-based generative design, particularly for targeting orphan receptors and previously unexplored macromole

Integration of AI in retrosynthesis and reaction prediction

Retrosynthesis and reaction prediction have always been fundamental in organic chemistry, guiding the design of synthetic routes. The intersection of material science and bioscience has given rise to the field of Computer-Assisted Organic Synthesis (CAOS), which has become an essential tool for synthetic planning. Recent advancements in reaction datasets and computational power have enabled the development of advanced machine learning (ML) and artificial intelligence (AI) models tailored for CAOS programs. These models can accurately predict both synthetic and retrosynthetic reactions, offering valuable insights for chemists in designing efficient synthetic pathways.A key development in CAOS is the integration of graph search algorithms to enhance single-step prediction accuracy. This innovation allows for the creation of CAOS programs capable of making comprehensive synthetic pathway predictions. By utilizing large datasets and computational resources, these programs improve the efficiency of synthetic planning, particularly in complex material and bio-interface studies. The application of AI and ML in CAOS not only speeds up the prediction of viable synthetic routes but also helps chemists navigate intricate reaction landscapes effectively. These tools are particularly valuable in exploring novel compounds at the bio-interface.Despite the progress, challenges remain, such as ensuring the reliability of predictions, improving interpretability, and refining algorithms for a wide range of chemical contexts. Ongoing collaboration between computational chemists, organic chemists, and data scientists is crucial to advancing CAOS applications. The combination of retrosynthesis, reaction prediction, and CAOS underscores the transformative potential of AI-driven tools in reshaping the future of synthetic chemistry, particularly at the interface of materials and bioscience. The expansion of AI's role in drug discovery further emphasizes the broad and significant impact these technologies are having in the field.

AI in Biomarker Discovery

Biomarkers play a crucial role in the early detection, diagnosis, prognosis, and treatment monitoring of diseases. They provide measurable indicators of disease states, therapeutic responses, or the biological effects of a treatment. In recent years, Artificial Intelligence (AI) has become an essential tool in the discovery of biomarkers, particularly in the context of complex diseases such as cancer, cardiovascular diseases, and neurological disorders. Traditional methods of biomarker discovery, including trial-and-error experimentation, are time-consuming, costly, and often inefficient. However, AI technologies, including machine learning (ML) and deep learning (DL), offer new ways to analyze large-scale datasets, identify novel biomarkers, and validate them faster and more accurately.This paper explores the application of AI in biomarker discovery, its methodologies, successes, and the challenges it faces.

Diagnostic Biomarkers: These are used to detect the presence of a disease or condition. For example, elevated levels of certain proteins in the blood, such as **PSA** (prostate-specific antigen) in prostate cancer, can indicate the presence of the disease.
Prognostic Biomarkers: These help predict the future course of a disease. They provide insights into the likely progression of a disease and how patients will respond to treatment.
Predictive Biomarkers:These biomarkers help to predict the response to a specific treatment, which is particularly valuable in the field of precision medicine. For instance, mutations in the **EGFR** gene predict the response to EGFR-targeted therapies in non-small cell lung cancer (NSCLC).
Pharmacodynamic Biomarkers: These provide information on how a drug is working in the body and whether it is having its intended effect.
Surrogate Biomarker**s:** These biomarkers substitute for clinical endpoints to measure how well a treatment is working, reducing the need for long-term studies.

The Role of AI in Drug Repurposing
Methods and Techniques for AI in Drug Repurposing
Network pharmacology involves the construction of drug-disease networks that represent the relationships between drugs, proteins, and diseases. AI models analyze these networks to predict which drugs could have an effect on diseases that share common molecular pathways.By analyzing protein-protein interaction networks and gene expression profiles, AI can suggest new potential drug targets and highlight drugs that could impact those targets.

Drug-Target Interaction Predictio**n:**AI models can predict the interactions between drugs and their molecular targets by analyzing chemical structures and biological data. These predictions are crucial in identifying drugs that can target previously unexplored biological pathways.

Algorithms such as **deep neural networks (DNNs)** and **graph convolutional networks (GCNs)** are used to predict drug-target interactions, helping to identify drugs that could be repurposed for diseases that share similar molecular characteristics.

Virtual Screening

AI-driven virtual screening methods simulate the interaction between small molecules (drugs) and biological targets (proteins, receptors). These techniques allow researchers to quickly screen large compound libraries to identify drugs that could potentially interact with the biological target of interest.

This technique has been widely used to identify potential repurposing candidates for diseases such as cancer, neurological disorders, and viral infections, where AI models simulate how existing drugs bind to viral proteins or tumor markers.

Challenges in AI-Driven Drug Repurposing
Despite its promising potential, AI-driven drug repurposing faces several challenges:
Data Quality and Availability: The success of AI models depends heavily on the quality and availability of data. Incomplete or biased datasets may lead to inaccurate predictions, and access to large, high-quality `datasets remains a challenge in some therapeutic areas.
Model Interpretability: Many AI models, especially deep learning models, operate as "black boxes," making it difficult to understand how they arrive at specific conclusions. This lack of transparency can hinder regulatory approval and clinical adoption.
Regulatory and ClinicalValidation: While AI can predict potential drug repurposing opportunities, clinical validation is required to confirm that these predictions hold true in real-world settings. This often

AI in Clinical Trial Design

Traditionally, designing a clinical trial is a complex and iterative process, often requiring months or years of planning to determine the appropriate methodology, endpoints, and patient cohorts. AI can help streamline this process by analyzing historical clinical trial data to optimize trial design and predict potential outcomes.

Data-Driven Study Design:

Patterns, improve the selectiAI algorithms can analyze large datasets from previous clinical trials to identify on of endpoints, and determine the best study design. This helps reduce the number of trials needed and increases the likelihood of a successful outcome. Machine learning models can predict which variables are most likely to influence the success of a clinical trial, aiding researchers in designing trials that are more efficient and targeted.

Optimal Dose Selection:

AI can be used to optimize the dosage levels of a drug by analyzing data from preclinical and early-phase clinical studies. Through modeling and simulation, AI helps predict the most effective doses that minimize side effects while maximizing therapeutic benefits

Predicting Trial Success:

By analyzing data from thousands of clinical trials, AI models can predict the likelihood of success or failure based on various factors such as the trial design,patient population, and drug characteristics. This predictive capability can guide decision-making, helping pharmaceutical companies avoid investing in high-risk trials.

AI in Data Analysis

One of the most powerful applications of AI in clinical trials is its ability to analyze vast amounts of data generated during the trials. Clinical trials often generate a tremendous volume of complex data, including genomic, proteomic, clinical, and patient-reported outcomes. AI technologies, particularly machine learning (ML) and deep learning (DL), are being increasingly used to extract meaningful insights from these data, allowing researchers to make more informed, timely, and accurate decisions.

Pattern Recognition in Complex Data

Clinical trials generate extensive datasets that include genomic sequences, protein interactions, and clinical data. Identifying meaningful patterns in this data is often challenging due to its volume and complexity. AI helps uncover these patterns by analyzing the interrelationships between drug compounds, biomarkers, and patient outcomes.

Machine learning algorithms can sift through vast amounts of data to recognize subtle correlations and associations that might not be immediately obvious to human researchers. For example, ML models can analyze the genetic makeup of patients and match it with their responses to a particular drug, enabling more precise prediction of treatment outcomes. This capacity to identify patterns improves personalized medicine strategies, ensuring that patients receive therapies most likely to work for their unique biological profiles.

Stratification of Patients

Patient stratification is the process of categorizing patients into subgroups based on shared characteristics, such as genetic makeup, comorbidities, and their responses to treatments. By effectively stratifying patients, AI can significantly enhance the precision of clinical trials.AI can automatically identify these subgroups by analyzing large datasets that include patient history, genetic data, and clinical outcomes. This process helps to determine which patients are most likely to benefit from a particulartherapy. For instance, AI can find correlations between specific genetic mutations and the efficacy of a drug, enabling the identification of patient populations that may respond well to a given treatment, thus improving the trial's overall success rate.

Advanced Statistical Methods

Traditional statistical methods can struggle to manage the complexity and volume of clinical trial data, especially when handling high-dimensional datasets. AI-driven algorithms, such as neural network**s** and **e**nsemble mode**ls**, provide more sophisticated ways to process this complex data.Neural networks, for example, are capable of identifying intricate patterns within data, such as nonlinear relationships between biomarkers and disease progression. Ensemble methods, which combine multiple machine learning models to improve prediction accuracy, can also offer more robust results when working with diverse and complex datasets. These advanced AI-driven techniques allow for more nuanced analysis, often identifying trends and patterns that conventional statistical methods may overlook. This capability is especially important for clinical trials that deal with large-scale multi-omics data or when considering many variables simultaneously.

AI in Multi-Omics Data Integration

Modern clinical trials increasingly rely on multi-omics data, which includes genomics, proteomics, metabolomics, and other biological data types. Integrating these different layers of biological information allows for a more comprehensive understanding of how diseases develop and how treatments can be optimized. However, the sheer complexity of multi-omics data makes it difficult to analyze using traditional methods.

.Limitations of Artificial Intelligence in Drug Discovery

While artificial intelligence (AI) offers significant promise in drug discovery, several challenges and limitations need careful consideration. A primary issue is the availability of appropriate data. AI-driven techniques typically require large, high-quality datasets for effective training . However, in many cases, the available data may be insufficient, of low quality, or inconsistent, which can undermine the accuracy and reliability of the results

AI systems heavily rely on comprehensive data for training machine learning (ML) models. Unfortunately, in some situations, accessible datasets may not be ideal, leading to the possibility of incorrect or suboptimal predictions. When data is limited, inconsistent, or of subpar quality, AI models cannot be trained effectively, and their performance iscompromised.Another significant challenge is the ethical considerations associated with AI-driven approaches. , AI techniques can perpetuate issues like fairness and bias

. If the data used to train an AI system is biased, or if it doesn't adequately represent diverse perspectives or patient populations, the resulting predictions may be skewed or invalid. It is crucial to address these ethical implications to ensure the responsible development of AI in drug discovery. Incorporating fairness and minimizing bias are essential steps to creating equitable and accurate predictive models.

For AI-generated drug candidates to move forward in development, they must undergo rigorous clinical trials and regulatory scrutiny. AI predictions can often provide an initial screening or hypothesis, but these need to be validated through traditional laboratory and clinical testing. The regulatory frameworks for AI-driven drug discovery are still evolving, and there may be hesitancy in adopting AI-based predictions without sufficient evidence of their reliability and accuracy.

Strategies and approaches to overcome current challenges

Incorporating artificial intelligence (AI) into drug discovery presents a strategic approach to addressing current challenges. A key focus is on optimizing data inputs, ensuring that datasets are diverse and of high quality to form a solid foundation for effective AI models.This helps tackle issues related to data accuracy and representativeness.Another critical strategy is the development of ethical guidelines and governance frameworks to guide responsible AI usage. This includes addressing concerns such as data privacy, consent, and ensuring ethical standards in AI applications. Collaboration across disciplines plays a pivotal role, combining the expertise of AI professionals with those in pharmacology, chemistry, and biology to enhance drug discovery processes. This fosters a synergistic integration of computational tools and domain-specific knowledge.Transparency in AI decision-making is essential, with the use of Explainable AI (XAI) providing clarity on AI-driven insights, particularly in the complex field of drug discovery. AI systems should also be adaptable, with the ability to continuously learn and stay relevant in this ever-evolving field.A comprehensive approach suggests integrating computational predictions with traditional experimental methods. This combination enhances the reliability and robustness of drug discovery. To address biases, a strong emphasis is placed on thorough evaluations and the development of mitigation strategies to ensure fairness and equity in AI-driven outcomes.Engagement with regulatory bodies is necessary to facilitate the acceptance and regulation of AI-based tools, ensuring their quality and validity in drug discovery. Additionally, fostering a culture of open collaboration and data sharing encourages collective progress in the field.Investing in education and skill development is crucial to bridging knowledge gaps and preparing a skilled workforce that can effectively navigate the intersection of AI and pharmaceutical sciences. Together, these strategies form a holistic framework to overcome existing challenges and optimize AI's role in advancing drug discovery.

REFERENCES

[1]. DiFrancesco, M., Hofer, J., Aradhya, A., Rufinus, J., Stoddart, J., Finocchiaro, S., et al. (2023). Discovery of small-molecule PD-1/PD-L1 antagonists through

combined virtualscreening and experimental validation. Comput. Biol. Chem. 102, 107804.doi:10.1016/j. compbiolchem.2022.107804

[2]. Abbasi, S., & Rahmani, A. M. (2023). Artificial intelligence and software modeling approaches in autonomous vehicles for safety management: A systematic review. Information, 14(10), 555. https://doi.org/10.3390/info1410055

[3]. Askr, H., Elgeldawi, E., Aboul Ella, H., Elshaier, Y. A., Gomaa, M. M., and Hassanien, A. E. (2023). Deep learning in drug discovery: an integrative review and future challenges. Artif. Intell.Rev. 56 (7), 5975–6037. doi:10.1007/s10462-02210306-1

[4]. Janet, J. P., Mervin, L., and Engkvist, O. (2023). Artificial intelligence in molecular de novo design: integration with experiment. Curr. Opin. Struct. Biol. 80, 102575. doi:10. 1016/j.sbi.2023.102575

[5]. Ahmad W., Gong Y., Abbas G., Khan K., Khan M., Ali G., et al. (2021b). Evolution of low-dimensional material-based field-effect transistors. Nanoscale 13 (10), 5162–5186. 10.1039/d0nr07548e - DOI - PubMed

[6]. Ahmad W., Ullah Z., Sonil N. I., Khan K. (2021a). Introduction, production, characterization and applications of defects in graphene. J. Mater. Sci. Mater. Electron. 32, 19991–20030. 10.1007/s10854-021-06575-1 - DOI

[7]. Ahmadi S. (2024). A comprehensive study on integration of big data and AI in financial industry and its effect on present and future opportunities. Int. J. Curr. Sci. Res. Rev. 7 (01). 10.47191/ijcsrr/v7-i1-07 - DOI